Get the Stockscreener App
38.75
1.55%
0.59
Pre-market:
39.25
0.50
+1.29%
Revolution Medicines Inc Stock (RVMD) Latest News
Revolution Medicines CFO Jack Anders sells $72,771 in stock - Investing.com India
Revolution Medicines’ general counsel sells $56,920 in stock - Investing.com
Revolution Medicines Executives Sell Shares - TradingView
Revolution Medicines COO Margaret Horn sells $119,385 in stock By Investing.com - Investing.com UK
Revolution Medicines executive sells shares worth $128,598 By Investing.com - Investing.com UK
Revolution Medicines Inc (RVMD) Should Be Considered For The Next Few Weeks - Stocks Register
Earnings To Watch: Revolution Medicines Inc (RVMD) Reports Q4 20 - GuruFocus.com
Revolution Medicines at Leerink Conference: Expanding RAS Inhibitor Reach By Investing.com - Investing.com Canada
Revolution Medicines’ SWOT analysis: RAS inhibitor stock shows promise amid clinical trials - Investing.com Canada
Revolution Medicines’ SWOT analysis: RAS inhibitor stock shows promise amid clinical trials By Investing.com - Investing.com South Africa
Revolution Medicines at Barclays Conference: Focus on Pancreatic Cancer Trials - Investing.com UK
Is Revolution Medicines, Inc. (RVMD) Among Stocks With At Least $20 Million In Insider Spending Recently? - Insider Monkey
10 Stocks With At Least $20 Million In Insider Spending Recently - Insider Monkey
Revolution Medicines’ Earnings Call: Positive Progress Amid Rising Costs - TipRanks
HC Wainwright Issues Positive Forecast for Revolution Medicines (NASDAQ:RVMD) Stock Price - Defense World
Revolution Medicines, Inc. (RVMD): Among the Cash-Rich Mid Cap Stocks to Buy Now - Yahoo Finance
10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey
Revolution Medicines’ (RVMD) “Outperform” Rating Reiterated at Wedbush - Armenian Reporter
Long Term Trading Analysis for (RVMD) - Stock Traders Daily
Wedbush Reaffirms Outperform Rating for Revolution Medicines (NASDAQ:RVMD) - Defense World
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insig - GuruFocus.com
Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus.com
Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Revolution Medicines Reports 2024 Financial Results and Progress - TipRanks
Earnings call transcript: Revolution Medicines Q4 2024 reflects strategic advancements - Investing.com India
Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress - GlobeNewswire
Revolution Medicines Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Revolution Medicines Q4 Net Loss Narrows -February 26, 2025 at 05:13 pm EST - Marketscreener.com
Earnings Flash (RVMD) Revolution Medicines Q4 Loss of $1.12 per Share vs. FactSet Est Loss of $0.99 - Marketscreener.com
Revolution Medicines, Inc. SEC 10-K Report - TradingView
Can Revolution Medicines' $2.3B War Chest Overcome Mounting Losses in Cancer Drug Race? - StockTitan
Earnings To Watch: Revolution Medicines Inc (RVMD) Reports Q4 2024 Result - Yahoo Finance
Revolution Medicines to Participate in March 2025 Investor Conferences - The Manila Times
Can Revolution Medicines' Triple Conference Appearance Signal Major Clinical Updates? - StockTitan
Rhumbline Advisers Acquires 24,473 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - Defense World
Revolution Medicines, Inc. (NASDAQ:RVMD) Receives $66.25 Consensus Target Price from Brokerages - Defense World
Revolution Medicines (RVMD) Expected to Announce Earnings on Wednesday - Defense World
Revolution Medicines to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Nasdaq
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025 - The Manila Times
Revolution Medicines to Report Financial Results for Fourth - GlobeNewswire
Revolution Medicines Q4 Earnings Coming: Will Their Cancer Drug Pipeline Show Progress? - StockTitan
(RVMD) Proactive Strategies - news.stocktradersdaily.com
Revolution Medicines' SWOT analysis: stock poised for growth amid clinical trials - MSN
Wilmington Savings Fund Society FSB Sells 15,167 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
SG Americas Securities LLC Sells 28,515 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Empowered Funds LLC Purchases New Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Mirae Asset Global Investments Co. Ltd. Sells 435 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) - Defense World
Wingate Wealth Advisors Inc. Buys New Stake in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
WCM Investment Management LLC Takes $6.80 Million Position in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):